MeSH Browser

MeSH Heading: Dactinomycin
Tree Number(s): D03.633.300.200; D04.345.566.252; D12.644.641.252
Unique ID: D003609
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D003609
Scope Note: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Entry Term(s): Actinomycin; Actinomycin D; Cosmegen; Cosmegen Lyovac; Lyovac-Cosmegen; Meractinomycin
Pharm Action: Anti-Bacterial Agents
Antibiotics, Antineoplastic
Protein Synthesis Inhibitors
Nucleic Acid Synthesis Inhibitors
Registry Number: 1CC1JFE158
Related Numbers: 50-76-0
CAS Type 1 Name: Actinomycin D
Public MeSH Note: 66; ACTINOMYCIN was heading 1963-95
History Note: 66; ACTINOMYCIN was heading 1963-95
Date Established: 1966/01/01
Date of Entry: 1999/01/01
Revision Date: 2017/05/24

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analogs & derivatives (AA)

analysis (AN)

antagonists & inhibitors (AI)

biosynthesis (BI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

economics (EC)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

urine (UR)

Concept UI: M0005644
Registry Number: 1CC1JFE158
Related Numbers: 50-76-0
Scope Note: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Terms: Dactinomycin Preferred Term
Term UI T010512
Date01/01/1999
LexicalTag NON
ThesaurusID; Meractinomycin
Term UI T010513
Date03/30/1977
LexicalTag NON
ThesaurusID; Actinomycin D
Term UI T010510
Date03/29/1974
LexicalTag NON
ThesaurusID

Dactinomycin MeSH Descriptor Data 2024